FILANA THERAPEUTICS INC
FLNANASDAQTrading Snapshot
- Day Range
- $0.63 – $0.66
- 52-Week Range
- $0.60 – $2.27
- Volume (shares)
- 346,902
- Avg Volume (shares)
- —
- Shares Outstanding
- 48.3M
- Next Earnings
- 2026-10-29
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 0.8x
- EPS (TTM)
- $-0.88
- Dividend Yield
- —
- Dilution (1yr)
- −99.0%
FILANA THERAPEUTICS INC
FLNA
StockOtter · stockotter.spaceAbout FILANA THERAPEUTICS INC
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells
Findings provide new insight into simufilam's effects on cellular stress responses and mitochondrial function New research demonstrates a 37% reduction in elevated ATF4, consistent with attenuation of the ATF4-associated
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, to
Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward
The U.S. Food and Drug Administration (FDA) on Tuesday removed a clinical hold on the investigational new drug application for Filana Therapeutics, Inc. (NASDAQ:FLNA).
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential inv
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Aug. 1
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Co